These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 31467082)

  • 1. Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.
    Engelman AN
    J Biol Chem; 2019 Oct; 294(41):15137-15157. PubMed ID: 31467082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric inhibition of HIV-1 integrase activity.
    Engelman A; Kessl JJ; Kvaratskhelia M
    Curr Opin Chem Biol; 2013 Jun; 17(3):339-45. PubMed ID: 23647983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
    Engelman AN; Cherepanov P
    FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
    Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
    J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Integrase Inhibitor Influences on HIV-1 Integration and Roles of LEDGF/p75 and HDGFL2 Host Factors.
    Singh PK; Li W; Bedwell GJ; Fadel HJ; Poeschla EM; Engelman AN
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain.
    Patel D; Antwi J; Koneru PC; Serrao E; Forli S; Kessl JJ; Feng L; Deng N; Levy RM; Fuchs JR; Olson AJ; Engelman AN; Bauman JD; Kvaratskhelia M; Arnold E
    J Biol Chem; 2016 Nov; 291(45):23569-23577. PubMed ID: 27645997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Competitive Interplay between Allosteric HIV-1 Integrase Inhibitor BI/D and LEDGF/p75 during the Early Stage of HIV-1 Replication Adversely Affects Inhibitor Potency.
    Feng L; Dharmarajan V; Serrao E; Hoyte A; Larue RC; Slaughter A; Sharma A; Plumb MR; Kessl JJ; Fuchs JR; Bushman FD; Engelman AN; Griffin PR; Kvaratskhelia M
    ACS Chem Biol; 2016 May; 11(5):1313-21. PubMed ID: 26910179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation.
    Jurado KA; Wang H; Slaughter A; Feng L; Kessl JJ; Koh Y; Wang W; Ballandras-Colas A; Patel PA; Fuchs JR; Kvaratskhelia M; Engelman A
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8690-5. PubMed ID: 23610442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the development of HIV integrase strand transfer inhibitors.
    Wang Y; Gu SX; He Q; Fan R
    Eur J Med Chem; 2021 Dec; 225():113787. PubMed ID: 34425310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.
    Le Rouzic E; Bonnard D; Chasset S; Bruneau JM; Chevreuil F; Le Strat F; Nguyen J; Beauvoir R; Amadori C; Brias J; Vomscheid S; Eiler S; Lévy N; Delelis O; Deprez E; Saïb A; Zamborlini A; Emiliani S; Ruff M; Ledoussal B; Moreau F; Benarous R
    Retrovirology; 2013 Nov; 10():144. PubMed ID: 24261564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
    Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
    Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors.
    Jurado KA; Engelman A
    Expert Rev Mol Med; 2013 Nov; 15():e14. PubMed ID: 24274067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinoline-based Protein-protein Interaction Inhibitors of LEDGF/p75 and HIV Integrase: An In Silico Study.
    Chhokar N; Kalra S; Chauhan M; Munshi A; Kumar R
    Curr Top Med Chem; 2018; 18(32):2800-2815. PubMed ID: 30747071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.
    Feng L; Sharma A; Slaughter A; Jena N; Koh Y; Shkriabai N; Larue RC; Patel PA; Mitsuya H; Kessl JJ; Engelman A; Fuchs JR; Kvaratskhelia M
    J Biol Chem; 2013 May; 288(22):15813-20. PubMed ID: 23615903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors.
    Koneru PC; Francis AC; Deng N; Rebensburg SV; Hoyte AC; Lindenberger J; Adu-Ampratwum D; Larue RC; Wempe MF; Engelman AN; Lyumkis D; Fuchs JR; Levy RM; Melikyan GB; Kvaratskhelia M
    Elife; 2019 May; 8():. PubMed ID: 31120420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.
    Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33572956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The allosteric HIV-1 integrase inhibitor BI-D affects virion maturation but does not influence packaging of a functional RNA genome.
    van Bel N; van der Velden Y; Bonnard D; Le Rouzic E; Das AT; Benarous R; Berkhout B
    PLoS One; 2014; 9(7):e103552. PubMed ID: 25072705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of multimerization selective inhibitors of HIV-1 integrase.
    Sharma A; Slaughter A; Jena N; Feng L; Kessl JJ; Fadel HJ; Malani N; Male F; Wu L; Poeschla E; Bushman FD; Fuchs JR; Kvaratskhelia M
    PLoS Pathog; 2014 May; 10(5):e1004171. PubMed ID: 24874515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
    Savarino A
    Retrovirology; 2007 Mar; 4():21. PubMed ID: 17374162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602.
    Ohata Y; Tomonaga M; Watanabe Y; Tomura K; Kimura K; Akaki T; Adachi K; Kodama EN; Matsuzaki Y; Hayashi H
    J Virol; 2022 Mar; 96(6):e0184321. PubMed ID: 35045265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.